Streetbeat News

Revenues

TRU

TransUnion has provided its financial outlook for FY24, expecting revenue between $4.098 billion and $4.138 billion, surpassing the estimated $4.085 billion. The company also projects adjusted EPS to be in the range of $3.78 to $3.90, compared to the estimated $3.82.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:24 am

TRU

TransUnion has provided its Q3 2024 revenue guidance of $1.044 billion to $1.060 billion, surpassing the estimated $1.030 billion. The company also expects adjusted EPS to be between $0.97 and $1.02, compared to the estimated $1.00.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:22 am

BC

Brunswick Corporation (BC) has lowered its FY2024 outlook, adjusting its EPS from $7.00-$8.00 to $5.00-$5.50 and sales from $5.20B-$5.40B, significantly below the estimated $7.15 and $5.97B respectively. The company also provided updated guidance on net sales, free cash flow, and share repurchases.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:19 am

TRU

TransUnion reported Q2 2024 adjusted EPS of $0.99, beating the estimate of $0.97. Sales were $1.041 billion, surpassing the expected $1.025 billion.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:18 am

PCG

PG&E (NYSE:PCG) reported Q2 2024 adjusted EPS of $0.31, beating the estimate of $0.30. Sales were $5.986 billion, surpassing the $5.902 billion estimate and marking a 13.16% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:16 am

XPRO

Expro Group has raised its FY2024 sales guidance from $1.60B-$1.70B to $1.70B-$1.75B, surpassing the $1.67B estimate. The company also refined its Adjusted EBITDA guidance to $350M-$375M. Third quarter revenue is expected to be $410M-$430M, with a sequential decrease but year-on-year growth of 14%.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:13 am

XPRO

Expro Group Holdings (NYSE:XPRO) reported Q2 2024 earnings per share of $0.27, meeting analyst expectations and showing a 58.82% increase from the previous year. The company also reported sales of $469.640 million, surpassing the $412.907 million estimate by 13.74% and marking an 18.32% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:11 am

DAWN

Ipsen and Day One Biopharmaceuticals have announced an exclusive ex-U.S. licensing agreement to commercialize tovorafenib for pediatric low grade glioma. Ipsen will handle regulatory and commercial activities outside the U.S., while Day One will receive an upfront payment of $111 million and up to $350 million in milestone payments.

Portfolio Pulse from charles@benzinga.com

July 25, 2024 | 10:10 am

HON

Honeywell International has adjusted its FY2024 guidance, lowering its adjusted EPS forecast from $10.15-$10.45 to $10.05-$10.25, while raising its sales guidance from $38.50B-$39.30B to $39.10B-$39.70B.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:07 am

WST

West Pharmaceutical Services has updated its full-year 2024 net sales guidance to a range of $2.87 billion to $2.9 billion, down from the previous range of $3 billion to $3.025 billion. The company also adjusted its full-year 2024 adjusted-diluted EPS guidance to $6.35 to $6.65, down from the prior range of $7.63 to $7.88. Capital spending for the year is expected to increase to $375 million from the previous estimate of $350 million.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:05 am